Literature DB >> 16625640

Laetrile treatment for cancer.

S Milazzo, E Ernst, S Lejeune, K Schmidt.   

Abstract

BACKGROUND: Laetrile is an unconventional therapy which has been used illegally for decades by cancer patients who together with some alternative therapists claim its effectiveness as an anti-cancer treatment. It has been often referred to as amygdalin, although the two are not the same.
OBJECTIVES: The aim of this review was to assess the alleged anti-cancer effect and the possible harms of Laetrile as a sole or adjunctive therapy in cancer treatment. SEARCH STRATEGY: We searched The Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (from 1951); EMBASE (from 1980); Allied and Complementary Medicine (AMED), Scirus, CancerLit, CINAHL (all from 1982); CAMbase (from 1998); the MetaRegister; the National Research Register and our own files. No language restrictions were imposed. SELECTION CRITERIA: Randomized clinical trials (RCTs) and non randomized controlled clinical trials (non-RCTs). DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trials for inclusion in the review, assessed study quality and extracted data. MAIN
RESULTS: No RCTs or non-RCTs were found, so no abstraction of outcome data could be performed in this systematic review AUTHORS'
CONCLUSIONS: The claim that Laetrile has beneficial effects for cancer patients is not supported by data from controlled clinical trials. This systematic review has clearly identified the need for randomised or controlled clinical trials assessing the effectiveness of Laetrile or amygdalin for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16625640     DOI: 10.1002/14651858.CD005476.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  7 in total

1.  Chinese Medicine Amygdalin and β-Glucosidase Combined with Antibody Enzymatic Prodrug System As A Feasible Antitumor Therapy.

Authors:  Yun-Long Li; Qiao-Xing Li; Rui-Jiang Liu; Xiang-Qian Shen
Journal:  Chin J Integr Med       Date:  2015-08-14       Impact factor: 1.978

2.  The effects of VitalStim on clinical and research thinking in dysphagia.

Authors:  Jeri A Logemann
Journal:  Dysphagia       Date:  2007-01-10       Impact factor: 3.438

Review 3.  Toxic phytochemicals and their potential risks for human cancer.

Authors:  Ann M Bode; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2014-10-27

4.  Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.

Authors:  Kimball C Atwood; Elizabeth Woeckner; Robert S Baratz; Wallace I Sampson
Journal:  Medscape J Med       Date:  2008-05-13

Review 5.  Laetrile for cancer: a systematic review of the clinical evidence.

Authors:  Stefania Milazzo; Stephane Lejeune; Edzard Ernst
Journal:  Support Care Cancer       Date:  2006-11-15       Impact factor: 3.359

6.  Problems and promises of innovation: why healthcare needs to rethink its love/hate relationship with the new.

Authors:  Mary Dixon-Woods; Rene Amalberti; Steve Goodman; Bo Bergman; Paul Glasziou
Journal:  BMJ Qual Saf       Date:  2011-04       Impact factor: 7.035

Review 7.  Laetrile treatment for cancer.

Authors:  Stefania Milazzo; Markus Horneber
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.